Rosuvastatin is a hypolipidemic means. Indications

• treatment of a hypercholesterolemia;
• prevention of cardiovascular disturbances.

Structure

• 1 tablet contains rosuvastatin - 20 mg;
• cellulose microcrystalline, lactose monohydrate, calcium hydrophosphate dihydrate; krospovidon; magnesium stearate;
• mix for a covering contains polyvinyl alcohol, the titan dioxide (E 171), polyethyleneglycol (macrogoal), talc, ferrous oxide yellow (E172), ferrous oxide red (E 172).

Contraindication

• to patients with hypersensitivity to rosuvastatin or to any of medicament excipients;
• to patients with an active disease of a liver, including with steady increase in serumal transaminases of an unknown etiology and any increases in transaminases in blood serum that exceeds the upper bound of norm (UBN) three times;
• to patients with heavy renal failures (clearance of creatinine <30 ml/min.);
• to patients with a myopathy;
• to patients who at the same time receive cyclosporine.

Route of administration

Rosuvastatin can be accepted irrespective of meal at any time.

cannot be divided

Tablet of 10 mg into parts therefore in case of need prescribing of rosuvastatin in a dose of 5 mg it is necessary to use medicaments of rosuvastatin of other producers with a possibility of dosing on 5 mg.

Treatment of a hypercholesterolemia

Recommended initial dose makes 5 or 10 mg orally 1 time a day as for patients, did not apply statines earlier, and transferred to medicament on intake of other inhibitor of GMG-KoA-reduktazy. When choosing an initial dose it is necessary to consider cholesterol level at each certain patient and risk of cardiovascular disturbances in the future and also a likelihood of development of side reactions. In case of need it is possible to raise a dose to the following level in 4 weeks. Considering that against the background of use of medicament in a dose of 40 mg the undesirable reactions arise more often than at smaller doses, finally patients need to titrate a dose to 40 mg with a heavy hypercholesterolemia and high risk of cardiovascular disturbances (in particular at patients with a family hypercholesterolemia) in which it was not succeeded to achieve the treatment goal at use of a dose of 20 mg and which will be under regular observation. At the beginning of administration of medicament in a dose of 40 mg supervision of experts is recommended.

Prevention of disturbances from a cardiovascular system

In a research reduction of risk of disturbances from a cardiovascular system rosuvastatin applied in a dose 20 mg a day.

Influence on kidneys

Proteinuria found as a result of the analysis on test strips and mainly canalicular origin was observed by

Feature of use

at the patients treated by high doses of rosuvastatin including 40 mg, and in most cases was temporary or faltering. The proteinuria was a harbinger of the acute or progressing disease of kidneys. Frequency of messages about serious the phenomena from kidneys in post-market researches is higher than 40 mg at use of a dose. At the patients taking the medicament in a dose of 40 mg it is necessary to check function of kidneys regularly.

Pregnant to

Rosuvastatin is contraindicated to

during pregnancy or feeding by a breast.

Children

Rosuvastatin is not recommended to be applied to children up to 10 years.

Drivers

At control of motor transport or work with other mechanisms should consider an opportunity dizziness the treatment period.

Overdose

is not present

Specific treatment of overdose. In case of overdose of the patient it is necessary to treat symptomatic and if necessary to accept the supporting actions. It is necessary to control functions of a liver and the UK level. The efficiency of a hemodialysis is improbable.

Side effects

from blood and lymphatic system: thrombocytopenia.

from the immune system: reactions of a giperchuvsnost, including angionevrochesky hypostasis.

from an endocrine system: diabetes.

Mental disorders: depression.

Storage conditions

In original packing at a temperature not above 25 °C.

to Store

out of children's reach.